-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Artificial intelligence (AI) blood testing technology was developed by Johns Hopkins Kimmel Cancer Center in nearly 800 samples of cancer patients and non-cancer patients, and found more than 90% of lung cancers
This detection method is called DELFI (for Early Intercepted DNA Fragment Evaluation), and it finds a unique pattern in the DNA fragments shed by cancer cells circulating in the blood, namely cell-free DNA (cfDNA)
Senior author Victor E.
The author pointed out that lung cancer is the most common cause of cancer deaths.
However, Velculescu explained that in the United States, less than 6% of people at risk of lung cancer have received the recommended low-dose computed tomography (LDCT) screening, although tens of thousands of deaths are expected to be avoided, while the world is screened.
DELFI technology uses blood tests to indirectly measure the way DNA is packaged in the nucleus by studying the size and quantity of circulating cfDNA from different regions of the genome
"In order to improve the sensitivity of early cancer detection, we have developed a genome-wide method to analyze cfDNA fragment profiles, called DELFI," the authors commented
In the reported study, researchers from Johns Hopkins University collaborated with researchers in Denmark and the Netherlands to perform cfDNA on blood samples of 365 individuals who participated in a 7-year study in Denmark called LUCAS for the first time.
The researchers wrote: "In this study, we used this method to detect and identify lung cancer in a prospectively collected real cohort that included patients with malignant and benign lung nodules as well as non-cancer patients, including those Patients with other clinical symptoms
"The DNA fragmentation pattern provides a significant fingerprint for early cancer detection, and we believe this may be the basis for the widely used liquid biopsy detection for lung cancer patients," added co-author Dr.
The team concluded: "Through this effort, we have provided a framework for bringing non-invasive liquid biopsy into the clinic, combining cfDNA fragments with other markers and LDCT for lung cancer detection
An unprecedented national clinical trial, Delfi-l101, sponsored by Delfi Diagnostics, a subsidiary of Johns Hopkins University, is evaluating a Delfi-based test among 1,700 participants in the United States, including healthy participants, lung cancer patients, and other cancers Patient
